IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.

IsoPlexis Corporation

Bruker Cellular Analysis provides solutions for understanding the life of single cells, offering applications across various stages of discovery and development in cellular research.

msh id	COM:ISOPLEXIS
symbol	ISO
name	IsoPlexis Corporation
homepage url	https://isoplexis.com
country	US
sector	Healthcare
industry	Medical - Devices
market	STOCKS
employee count	290
crunchbase url	-
linkedin url	-
founders	-

market cap	30.28M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.21
growth cost of revenue	1.08
growth depreciation and amortization	13.27
growth ebitda	-0.21
growth ebitda ratio	-0.25
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.62
growth gross profit	-1.11
growth gross profit ratio	-1.11

COM:ISOPLEXIS

Bruker Cellular Analysis

Last Close

0.76

20/03 20:00

Market Cap

30.28M

Beta: -

Volume Today

111.02K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	113.25M
cost of revenue	113.25M
depreciation and amortization	9.69M
ebitda	-91.54M
ebitda ratio	-5.46
eps	-2.94
eps diluted	-2.94
operating expenses	95.57M
operating income	-101.23M
operating income ratio	-6.04

accounts receivables	-700K
capital expenditure	-7.82M
cash at beginning of period	126.57M
cash at end of period	37.47M
inventory	27.52M
working capital ttm	54.15M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-